A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7268 in Healthy Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2013
At a glance
- Drugs AZD 7268 (Primary)
- Indications Anxiety disorders; Depression
- Focus Adverse reactions
- Acronyms JSAD
- 11 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2009 Planned end date changed from 1 Aug 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
- 06 Oct 2009 Planned number of patients changed from 40 to 56 as reported by ClinicalTrials.gov.